Analyst Price Target is $9.25
▲ +53.15% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Recursion Pharmaceuticals in the last 3 months. The average price target is $9.25, with a high forecast of $12.00 and a low forecast of $6.00. The average price target represents a 53.15% upside from the last price of $6.04.
Current Consensus is
Hold
The current consensus among 5 contributing investment analysts is to hold stock in Recursion Pharmaceuticals. This rating has held steady since August 2024, when it changed from a Moderate Buy consensus rating.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Read More
